Curetopia raises $1.77M to advance decentralized biotech using Solana

Curetopia has secured $1.77 million in funding to accelerate decentralized biotech initiatives aimed at developing treatments for rare diseases. Built on Solana, Curetopia’s blockchain-based model enables patient communities to participate in drug development through tokenized ownership, addressing gaps left by traditional funding sources such as the National Institutes of Health (NIH) and the National Science Foundation (NSF). The fundraising, supported by over 1,000 contributors, underscores the rising momentum of decentralized science (DeSci) as an alternative to conventional biotech funding.

Operating as a decentralized autonomous organization (DAO) on Bio Protocol with backing from Binance, Curetopia focuses on the estimated $1 trillion rare disease market, historically overlooked by major pharmaceutical firms. By leveraging blockchain-based crowdfunding, the DAO empowers patients and researchers to jointly finance drug discovery projects, sharing intellectual property through tokenized assets.

advertise

A significant milestone for Curetopia includes the identification of a potential treatment for AARS2 progressive leukoencephalopathy, a fatal mitochondrial disease with no approved therapies. This discovery emerged from a screening of 8,500 repurposable compounds using yeast models, marking one of the first crypto-backed biotech projects to approach commercialization. The DAO is currently filing a provisional patent for this discovery, with any future commercialization proceeds reinvested into the community-driven initiative.

Curetopia’s model integrates patient engagement into drug development, an approach championed by its founder, Dr. Ethan Perlstein, a Harvard PhD and former Y Combinator participant. Perlstein previously led a rare disease treatment to Phase 3 trials for just $5 million, a fraction of the cost seen in traditional pharmaceutical development. He asserts that decentralization allows rare disease patients to directly influence treatment innovation, disrupting the conventional research model driven by commercial incentives.

Participants in Curetopia’s decentralized clinical trials receive CURES tokens, granting them a stake in the success of the therapies they help develop. The DAO’s approach, which incorporates drug repurposing, tokenized intellectual property, and community-led trials, aims to fast-track regulatory approvals while significantly reducing development costs.

advertise

Curetopia has also partnered with COMBINEDBrain and Unravel Biosciences to expand its drug screening services, benefiting over 100 genetic neurodevelopmental disorder organizations. Additionally, the DAO seeks to leverage regulatory advantages such as FDA Priority Review Vouchers and Orphan Drug Designation, which provide expedited pathways and financial incentives for rare disease therapeutics.